Additional Iressa Study Closed Due To Lack Of Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Data monitoring committee recommends closing National Cancer Institute-sponsored trial studying gefitinib as a maintenance therapy in non-small cell lung cancer patients who responded to chemo. NCI trial is the second study in recent months in which Iressa failed to demonstrate a survival benefit.
You may also be interested in...
AstraZeneca's Iressa Produces Effect In Subpopulation, ASCO Data Show
Initial Phase II study shows 62% response rate in Korean, non-smoking females with non-small cell lung cancer. Identification of Iressa (gefitinib) responders and the role of EGFR mutations are major themes at the American Society of Clinical Oncology annual meeting.
AstraZeneca's Iressa Produces Effect In Subpopulation, ASCO Data Show
Initial Phase II study shows 62% response rate in Korean, non-smoking females with non-small cell lung cancer. Identification of Iressa (gefitinib) responders and the role of EGFR mutations are major themes at the American Society of Clinical Oncology annual meeting.
Zarnestra Phase III Data Needed Pre-Approval, Oncology Committee Says
FDA's Oncologic Drugs Advisory Committee votes 7 to 4 against recommending accelerated approval of J&J's tipifarnib. Data from the Phase III trial are necessary to identify the appropriate patient population for the oncologic, members say.